Short communication: Severe immune suppression in patients infected with R5-tropic HIV-1 strains is associated with increased gp120 net charge at variable regions

AIDS Research and Human Retroviruses

Volumn 27, Issue 9, 2011, Pages 965-967

  Seclén, Eduardo ^a   Soriano, Vincent ^a   Del Mar González, María ^a   González Lahoz, Juan ^a   Poveda, Eva ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 120;

ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; DISEASE SEVERITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VIRUS STRAIN;

CD4 LYMPHOCYTE COUNT; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE TOLERANCE; RECEPTORS, CCR5; RECEPTORS, HIV; VIRAL TROPISM;

EID: 80052074749     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2010.0359     Document Type: Article

References (10)

1. Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, and Moyle G: The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 2008;46:1617-1623. (Pubitemid 351706746)
2. Pope M and Haase A: Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 2003;9:847-852. (Pubitemid 36889925)
3. Schuitemaker H, Koot M, Kootstra N, et al.: Biological phe-notype of HIV type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J Virol 1992;66:1354-1360.
4. Repits J, Oberg M, Esbjornsson J, et al.: Selection of HIV type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J Gen Virol 2005;86:2859-2869. (Pubitemid 41410478)
5. Repits J, Sterjovski J, Badia-Martinez D, et al.: Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology 2008;379:125-134.
6. Poveda E, Briz V, Roulet V, et al.: Correlation between a phenotypic assay and three bioinformatic tools for determining HIV co-receptor use. AIDS 2007;21:1487-1490. (Pubitemid 46988013)
7. Seclén E, Garrido C, González MM, et al.: High sensitivity of specific genotypic tools for detection of X4 variants in anti-retroviral- experienced patients suitable to be treated with CCR5 antagonists.JAntimicrob Chemother 2010;65:1486-1492.
8. Poveda E, Seclén E, González MM, et al.: Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J Antimicrob Chemother 2009;63:1006-1010.
9. Delobel P, Nugeyre M, Cazabat M, et al.: Population-based sequencing of the V3 region of env for predicting the cor-eceptor usage of HIV type 1 quasispecies. J Clin Microbiol 2007;45:1572-1580. (Pubitemid 46762416)
10. Davis H, Morgan J, and Yarmush M: Polybrene increases retrovirus gene transfer efficiency by enhancing receptor-independent virus adsorption on target cell membranes. Biophys Chem 2002;97:159-117.